Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8784891 | Advances in Radiation Oncology | 2018 | 28 Pages |
Abstract
This is the first study to report long-term outcomes of MMC with 5-fluorouracil-based adjuvant chemoradiation in periampullary cancers. Because MMC may be considered in DNA repair-deficient carcinomas, randomized trials are needed to determine the true benefit of adjuvant MMC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Kathryn J. PhD, Lauren M. BS, Marianna MS, Joseph M. MD, MSc, Amol K. MD, Irina Usach, Alison P. MHS, PhD, Charles J. MD, Larry T. BSN, Ralph H. MD, John L. MD, Daniel A. MD, Ross A. MD,